• Publications
  • Influence
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
JAK2 617V>F mutation occurs in a homozygous state in 25% to 30% of patients with polycythemia vera (PV) and 2% to 4% with essential thrombocythemia (ET). Whether homozygosity associates with distinctExpand
  • 384
  • 17
  • PDF
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
PURPOSE The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF). This studyExpand
  • 312
  • 13
  • PDF
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.
Among 994 patients with essential thrombocythemia (ET) who were genotyped for the MPLW515L/K mutation, 30 patients carrying the mutation were identified (3.0%), 8 of whom also displayed the JAK2V671FExpand
  • 215
  • 12
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.
A total of 186 patients with primary myelofibrosis (PMF) were genotyped for JAK2V617F at diagnosis aimed at analyzing the correlation of mutational status and mutated allele burden with outcomeExpand
  • 176
  • 11
  • PDF
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
Few investigators have evaluated the usefulness of the JAK2 V617F mutation for explaining the phenotypic variations and for predicting the risk of major clinical events in primary myelofibrosisExpand
  • 229
  • 8
  • PDF
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia
istic upmodulation of CD20 and downmodulation of CD10, comparable to the immunophenotypic modulation observed in vivo. In contrast, the viable 7-AAD-negative cells retained their originalExpand
  • 242
  • 7
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.
In an international collaborative study, a central histologic review identified 891 patients with essential thrombocythemia, strictly defined by World Health Organization criteria. After a medianExpand
  • 246
  • 7
  • PDF
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and
Diagnosis of essential thrombocythemia (ET) has been updated in the last World Health Organization (WHO) classification. We developed a prognostic model to predict survival at diagnosis, named IPSETExpand
  • 167
  • 6
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia
Variable proportions of mutant alleles are found in patients with JAK2 (V617F)-positive myeloproliferative disorders. This study shows that this variable mutant allele burden influences the clinicalExpand
  • 144
  • 6
  • PDF
Thrombosis in primary myelofibrosis: incidence and risk factors.
We assessed frequency and predictive factors for major cardiovascular (CV) events in 707 patients with primary myelofibrosis (PMF) followed in 4 European institutions. A total of 236 deaths (33%)Expand
  • 157
  • 6